D. Clarke‐Pearson
Journal of Clinical Oncology · 1988–2003
A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 65 researchers here, as inferred from the citation graph.
Whom D. Clarke‐Pearson trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts D. Clarke‐Pearson overall
- Karimollah Hajian-Tilaki
- Morgan N. Price
- V. de Vogel
- K. Kroenke
- F. Nahm
- Rune Halvorsen
- M. Maloof
- Jay P. Singh
- John Muschelli
- Jalal Al-Tamimi
Papers from D. Clarke‐Pearson's perspective
Ordered by how strongly the researchers D. Clarke‐Pearson trusts endorse each paper. Same corpus, a different order for every researcher.
- A Class of Statistics with Asymptotically Normal Distribution
- Signal detection theory and psychophysics
- Importance of replication in microarray gene expression studies: statistical methods and evidence from repetitive cDNA hybridizations. (Proceedings of the National Academy of Sciences of the United States of America)
- Different Outcomes of the Wilcoxon—Mann—Whitney Test from Different Statistics Packages
- Individual Comparisons by Ranking Methods
- Standardisation of spirometry (European Respiratory Journal)
- On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other
- Adverse events associated with prescription drug cost-sharing among poor and elderly persons. (Journal of the American Medical Association (JAMA))
- On a Test Whether Two Samples are from the Same Population
- Statistical issues with microarrays: processing and analysis. (Trends in Genetics)
Their papers
- Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. (1988)
- Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. (2003) — 2,032 citations
- Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. (2003) — 597 citations